RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Pharmacological Articles

If approved by FDA, IV tramadol would be the first Schedule IV intravenous opioid in the US.
AcelRx is planning on resubmitting an NDA for DSUVIA to FDA in Q2 2018.
Elevated use of gabapentinoid misuse and abuse may be a problem with monitoring opioids.
Small doses could help children suffering from various types of inflammation and pain.
With appropriate treatment and follow-up, individuals can reach sustained long-term remission from OUD.
Nonopioid Management Just as Impactful as Opioids for Knee/OA Pain
Chronic neuropathy treatment does not offer much pain relief for patients.
Further studies of the long-term use of cyclobenzaprine for chronic pain management are needed to confirm its efficacy.
Opioid antagonists, such as naltrexone and naloxone, may help reduce side effects and address drug deficiencies in chronic pain treatment.
FDA approval of biosimilars in comparison to biologics for the treatment of chronic pain raises issues of efficacy.
UN calls untreated pain cruel and inhumane, yet in the US chronic pain patients are losing access to needed opioid therapy to manage severe, intractable pain conditions.
The best approaches to manage pain relief to most effectively address post-surgical pain.
Ask the Expert: A discussion of the pain relief potential from Na1.7 Inhibitors for neuropathic pain disorders.
Readers raise questions about the one-sided view of the so-called opioid-epidemic, hormone therapy, and long-term opioid care.
Expert give you advice on how to switch from Opanan ER to another long-acting opioid.
SHOW MAIN MENU
SHOW SUB MENU